Markets Bounce Back Behind Mag-7 Momentum

The tech-heavy Nasdaq led the way higher - +259 points, +1.45% - followed by the S&P +0.97% and the blue-chip Dow +0.30%.

The tech-heavy Nasdaq led the way higher - +259 points, +1.45% - followed by the S&P +0.97% and the blue-chip Dow +0.30%.

Is Humana a Deep Value Stock to Buy?

Humana shares have fallen from over $560 to under $250. Could now be the time to buy?

Humana shares have fallen from over $560 to under $250. Could now be the time to buy?

Top Research Reports for JPMorgan Chase, Medtronic & Shopify

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Medtronic plc (MDT) and Shopify Inc. (SHOP), as well as a micro-cap stock Perma-Pipe International Holdings, Inc. (PPIH).

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Medtronic plc (MDT) and Shopify Inc. (SHOP), as well as a micro-cap stock Perma-Pipe International Holdings, Inc. (PPIH).

Chinese Stocks Slump: Time to Buy the Dip?

Chinese stocks cratered on Tuesday. Stock Strategist Andrew Rocco explains how the fundamentals and technicals suggest that the pullback is likely a buying opportunity rather than a top.

Chinese stocks cratered on Tuesday. Stock Strategist Andrew Rocco explains how the fundamentals and technicals suggest that the pullback is likely a buying opportunity rather than a top.

The Cheapest Mag 7 Stocks in 2024

Tracey Ryniec has often discussed how value investors can own both growth and value stocks. (They are not limited only to value stocks.) Why not look at the largest big-cap growth stocks out there?

Tracey Ryniec has often discussed how value investors can own both growth and value stocks. (They are not limited only to value stocks.) Why not look at the largest big-cap growth stocks out there?

New Strong Buy Stocks for October 8th

This commercial-stage biopharmaceutical company which is focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 9.7% over the last 60 days.

This commercial-stage biopharmaceutical company which is focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 9.7% over the last 60 days.

PFP 10/8: CPI and PPI Inflation Reports On Deck for This Week

The main events on the economic-report docket for this week are the inflation reports: one being the Consumer Price Index.

The main events on the economic-report docket for this week are the inflation reports: one being the Consumer Price Index.

NVIDIA Stock Up 155% The Year: Still a Buy? Related ETFs to Consider

If you are worried about NVIDIA's negative ESP and still take advantage of the AI boom and prospective high growth trajectory, you can stay invested in the NVDA-heavy semiconductor exchange-traded funds.

If you are worried about NVIDIA's negative ESP and still take advantage of the AI boom and prospective high growth trajectory, you can stay invested in the NVDA-heavy semiconductor exchange-traded funds.